GANX net incomeQ2 2026-$4.68M
GANX net income was -$4.68M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.81M a year earlier. For the full fiscal 2025 it was -$20.16M, compared with -$20.41M in fiscal 2024.
Gain Therapeutics Inc. (GANX) financials
For the twelve months ended Jun 30, 2026, Gain Therapeutics Inc. reported -$20.11M of net income.
- Net income, TTM
- -$20.11M
- EPS, diluted, TTM
- -$0.50
- Cash
- $13.08M
- Total debt
- $343.7K
- Market cap
- $47.6M
FY2020FY2023
FY2020FY2025
FY2020FY2024
GANX revenue and earnings growth
GANX EPSQ2 2026-$0.11
GANX diluted EPS was -$0.11 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.61.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $55.2K | $140.1K | $165.0K | $28.9K |
| Research and development | $10.21M | $10.79M | $11.52M | $8.38M | $7.16M | $2.26M |
| Selling, general and admin | $8.50M | $9.56M | $10.79M | $9.54M | $6.83M | $1.25M |
| Operating income | -$18.71M | -$20.35M | -$22.25M | -$17.78M | -$13.83M | -$3.48M |
| Pre-tax income | -$19.30M | -$19.87M | -$22.19M | -$17.50M | -$13.89M | -$3.57M |
| Income tax | $861.1K | $536.8K | $79.3K | $93.0K | $4.0K | $5.4K |
| Net income | -$20.16M | -$20.41M | -$22.27M | -$17.59M | -$13.89M | -$3.58M |
| EPS, basic | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| EPS, diluted | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| Diluted shares | 33.0M | 22.9M | 13.0M | 11.9M | 10.2M | 2.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $20.84M | $10.42M | $11.83M | $7.34M | $36.91M | $7.50M |
| Short-term investments | - | - | $5.00M | $12.83M | - | - |
| Receivables | - | - | - | - | - | $8.5K |
| Current assets | $22.24M | $11.60M | $17.78M | $21.09M | $37.72M | $8.99M |
| Total assets | $22.82M | $12.12M | $18.61M | $24.10M | $38.99M | $9.60M |
| Current liabilities | $3.35M | $3.91M | $4.95M | $4.13M | $2.55M | $2.11M |
| Short-term debt | $100.9K | $110.2K | $118.8K | $108.1K | $103.8K | $22.6K |
| Long-term debt | $300.1K | $328.3K | $449.1K | $495.3K | $590.5K | $715.7K |
| Total debt | $401.0K | $438.5K | $567.9K | $603.4K | $694.3K | $738.3K |
| Total liabilities | $4.25M | $4.78M | $6.03M | $5.22M | $4.17M | $3.40M |
| Shareholders' equity | $18.56M | $7.34M | $12.58M | $18.88M | $34.82M | $6.20M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.47M | -$18.87M | -$18.87M | -$14.69M | -$12.37M | -$3.24M |
| Capital expenditures | - | $22.5K | $15.4K | $119.0K | $94.2K | $20.8K |
| Free cash flow | - | -$18.90M | -$18.88M | -$14.81M | -$12.46M | -$3.26M |
| Investing cash flow | - | $4.98M | $10.22M | -$14.77M | -$94.2K | -$20.8K |
| Financing cash flow | $28.45M | $13.01M | $12.64M | -$78.8K | $41.77M | $10.49M |
| Stock-based compensation | $1.80M | $2.39M | $3.26M | $1.53M | $839.4K | $81.6K |
| Depreciation and amortization | $94.0K | $84.1K | $83.6K | $64.2K | $15.5K | $9.6K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -60.6% | -15.1% | 471.3% | - |
| Operating margin | - | - | -40328.3% | -12688.1% | -8379.8% | -12047.5% |
| Net margin | - | - | -40354.3% | -12555.1% | -8418.9% | -12387.7% |
| Free cash flow margin | - | - | -34217.5% | -10571.2% | -7551.7% | -11291.4% |
| Return on equity | -108.6% | -278.1% | -177.0% | -93.2% | -39.9% | -57.7% |
| Return on assets | -88.4% | -168.4% | -119.7% | -73.0% | -35.6% | -37.3% |
| Current ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 | 4.25 |
| Debt to equity | 0.02 | 0.06 | 0.05 | 0.03 | 0.02 | 0.12 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | $2.14M | $2.76M | $2.35M | $2.85M | $2.76M | $2.26M | $1.22M | $2.62M | $4.44M | $2.51M | $2.37M | $2.37M |
| Selling, general and admin | $2.54M | $2.59M | $2.12M | $1.94M | $2.33M | $2.11M | $2.11M | $1.84M | $3.75M | $1.87M | $2.03M | $2.52M |
| Operating income | -$4.68M | -$5.35M | -$4.47M | -$4.79M | -$5.09M | -$4.37M | -$3.33M | -$4.46M | -$8.18M | -$4.38M | -$4.41M | -$4.89M |
| Pre-tax income | -$4.57M | -$5.43M | -$4.47M | -$4.74M | -$5.67M | -$4.43M | -$3.26M | -$4.47M | -$8.14M | -$3.99M | -$4.71M | -$4.70M |
| Income tax | $104.1K | $183.1K | $70.1K | $549.3K | $141.2K | $100.5K | $504.7K | $11.0K | $1.2K | $19.9K | $14.5K | $21.5K |
| Net income | -$4.68M | -$5.61M | -$4.54M | -$5.28M | -$5.81M | -$4.53M | -$3.77M | -$4.49M | -$8.14M | -$4.01M | -$4.72M | -$4.72M |
| EPS, basic | -$0.11 | -$0.13 | -$0.11 | -$0.15 | -$0.19 | -$0.16 | - | -$0.17 | -$0.42 | -$0.22 | -$0.29 | -$0.37 |
| EPS, diluted | -$0.11 | -$0.13 | -$0.11 | -$0.15 | -$0.19 | -$0.16 | - | -$0.17 | -$0.42 | -$0.22 | -$0.29 | -$0.37 |
| Diluted shares | 42.9M | 42.2M | - | 35.0M | 30.3M | 28.7M | - | 26.5M | 19.2M | 18.0M | - | 12.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.08M | $16.54M | $20.84M | $8.81M | $6.73M | $9.10M | $10.42M | $12.08M | $16.97M | $10.67M | $11.83M | $4.30M |
| Short-term investments | - | - | - | - | - | - | - | - | - | $2.02M | $5.00M | $7.96M |
| Current assets | $14.97M | $18.22M | $22.24M | $10.52M | $9.31M | $11.15M | $11.60M | $13.74M | $18.54M | $13.86M | $17.78M | $13.24M |
| Total assets | $15.42M | $18.74M | $22.82M | $10.97M | $9.83M | $11.62M | $12.12M | $14.37M | $19.20M | $14.58M | $18.61M | $14.10M |
| Current liabilities | $3.43M | $3.89M | $3.35M | $4.17M | $5.20M | $5.03M | $3.91M | $4.59M | $6.52M | $5.00M | $4.95M | $5.76M |
| Short-term debt | $123.6K | $100.3K | $100.9K | $125.5K | $126.1K | $113.1K | $110.2K | $118.3K | $111.1K | $110.8K | $118.8K | $109.3K |
| Long-term debt | $220.1K | $273.3K | $300.1K | $298.8K | $325.4K | $314.5K | $328.3K | $376.1K | $375.4K | $396.8K | $449.1K | $434.9K |
| Total debt | $343.7K | $373.5K | $401.0K | $424.3K | $451.5K | $427.6K | $438.5K | $494.4K | $486.4K | $507.7K | $567.9K | $544.2K |
| Total liabilities | $4.13M | $4.73M | $4.25M | $5.06M | $6.14M | $5.84M | $4.78M | $5.46M | $7.41M | $5.94M | $6.03M | $6.77M |
| Shareholders' equity | $11.29M | $14.01M | $18.56M | $5.91M | $3.70M | $5.78M | $7.34M | $8.91M | $11.78M | $8.64M | $12.58M | $7.33M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.68M | -$4.73M | -$4.62M | -$4.93M | -$5.10M | -$3.82M | -$3.45M | -$6.08M | -$5.76M | -$3.59M | -$5.66M | -$3.97M |
| Capital expenditures | - | - | - | - | - | - | $945 | $1 | - | - | $19 | $650 |
| Free cash flow | - | - | - | - | - | - | -$3.46M | -$6.08M | - | - | -$5.66M | -$3.97M |
| Investing cash flow | - | - | - | - | - | - | -$43.4K | -$1 | $2.00M | $3.02M | $3.14M | $1.93M |
| Financing cash flow | $1.37M | $404.3K | $16.55M | $7.03M | $2.47M | $2.40M | $2.31M | $808.7K | $10.04M | -$145.8K | $9.56M | $134.5K |
| Stock-based compensation | $566.0K | $403.5K | $401.7K | $460.0K | $522.0K | $419.5K | $359.3K | $357.5K | $1.48M | $190.4K | $555.1K | $907.3K |
| Depreciation and amortization | $27.2K | $21.3K | $28.2K | $22.8K | $22.3K | $20.7K | $21.3K | $21.6K | $20.6K | $20.5K | $23.6K | $20.5K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.36 | 4.69 | 6.63 | 2.52 | 1.79 | 2.22 | 2.97 | 2.99 | 2.84 | 2.77 | 3.59 | 2.30 |
| Debt to equity | 0.03 | 0.03 | 0.02 | 0.07 | 0.12 | 0.07 | 0.06 | 0.06 | 0.04 | 0.06 | 0.05 | 0.07 |
Source: XBRL data Gain Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GANX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GANX | - | - | -$20.11M | - | $47.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
GANX FAQ
5 questionsIs GANX profitable?
No. Gain Therapeutics Inc. reported a net loss of $20.11M for the twelve months ended Jun 30, 2026.How much cash and debt does GANX have?
Gain Therapeutics Inc. reported $13.08M in cash and cash equivalents and $343.7K of debt on its most recent balance sheet in SEC filings.What is GANX earnings per share?
Diluted earnings per share were -$0.50 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did GANX last report financial results?
The latest statements here come from Gain Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this GANX financial data come from?
Quantisnow builds these statements from the structured XBRL data Gain Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.